NervGen Refiles Q2 2026 Interim Financials, Restating Loss to Income on Warrant Fix

summarizeSummary

NervGen refiled its Q2 2026 interim financials, restating the quarter from a C$29.2M net loss to C$10.8M net income after fixing option and warrant valuation errors. The restatement is non-cash, cash stays at C$86.8M, but a material weakness in internal controls was disclosed.

check_boxKey Events · Corporate Governance and Compliance · NGEN

• Q2 2026 Interim Financials Refiled

  The August 13, 2026 interim statements and MD&A are withdrawn and replaced; the audit committee determined they should no longer be relied upon.

• Restatement Flips Quarter to Net Income

  Q2 2026 goes from a previously reported C$29.2M net loss to C$10.8M net income (basic EPS C$0.12 vs C$(0.32)); the six-month figure moves from a C$30.9M loss to C$8.9M income.

• Warrant Derivative Cut by C$29.6M

  June 30, 2026 warrant derivative restated from C$68,625,899 to C$39,062,252, with the deficit reduced from C$177,656,300 to C$133,287,915. All adjustments are non-cash.

• Material Weakness in Internal Controls

  Miscalculated annualized volatility in the Black-Scholes-Merton model and insufficient segregation of duties in finance; errors date back to fiscal 2020.

auto_awesomeAnalysis · NGEN · Life Sciences

NervGen's audit committee concluded the Q2 2026 interim statements filed August 13, 2026 can no longer be relied upon, and this 6-K/A replaces them. The error was a miscalculated annualized volatility input in the Black-Scholes-Merton model used to value options and warrant derivatives, plus share issuance costs booked to Common Shares instead of expensed. The restated quarter flips from a C$29.2M net loss to C$10.8M net income, and the June 30, 2026 warrant derivative drops from C$68.6M to C$39.1M. None of this touches cash: the company still holds C$86.8M and says that funds operations for the next 12 months. The real issue is control quality, not solvency. Management disclosed a material weakness in internal controls, with responsibility for complex accounting concentrated in too few finance staff and no documented volatility methodology. The company has hired an Accounting Manager (October 5, 2026) and a Director of Contracts (August 12, 2026) and expects a documented valuation memo before the September 30, 2026 filing. Until those controls are tested, reported numbers carry execution risk, and the restatement itself raises the odds of regulatory inquiries and added professional costs.